HLA等位基因单核苷酸多态性与未治疗HIV-1感染者病毒载量的关联
研究在START试验2440例未接受抗逆转录病毒治疗、人口学特征多样的参与者中,用定制SNP芯片基因型数据、推算的HLA等位基因及多元线性回归全基因组筛查SNP与病毒载量的关联。发现MHC I类区域SNP与病毒载量达全基因组显著关联,效应量为0.14–0.39 log10 copies/mL,并识别出多个与病毒载量显著相关的HLA等位基因。
要点
- MHC I类区域是HIV-1病毒载量的主要宿主决定因素。
- 多个HLA等位基因与病毒载量显著相关,支持SNP筛查结果。
- 全基因组关联研究仅属筛查工具,需后续验证。
核心结论
- MHC I类区域SNP及HLA等位基因与未治疗HIV-1感染者病毒载量显著关联,且该遗传效应跨人群共享。
研究设计与样本
- 基于START试验2440例未接受抗逆转录病毒治疗、人口学特征多样的参与者,采用定制SNP阵列基因型数据与推算HLA等位基因,以多元线性回归进行全基因组筛查。
主要发现
- MHC I类区域SNP与病毒载量呈全基因组显著关联,效应量为0.14–0.39 log10 copies/mL。
- 多个HLA等位基因与病毒载量显著相关,与SNP结果相互印证。
临床怎么用
- 提示MHC I类区域HLA变异可作为HIV-1病毒载量控制的宿主遗传标志,跨人群适用。
局限性
- 作者指出全基因组关联研究仅属筛查工具,需后续验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impact of variation in host genetics on replication of human immunodeficiency virus type 1 (HIV-1) in demographically diverse populations remains uncertain. In the current study, we performed a genome-wide screen for associations of single-nucleotide polymorphisms (SNPs) to viral load (VL) in antiretroviral therapy-naive participants (n = 2440) with varying demographics from the Strategic Timing of AntiRetroviral Treatment (START) trial. Associations were assessed using genotypic data generated by a customized SNP array, imputed HLA alleles, and multiple linear regression. Genome-wide significant associations between SNPs and VL were observed in the major histocompatibility complex class I region (MHC I), with effect sizes ranging between 0.14 and 0.39 log10 VL (copies/mL). Supporting the SNP findings, we identified several HLA alleles significantly associated with VL, extending prior observations that the (MHC I) is a major host determinant of HIV-1 control with shared genetic variants across diverse populations and underscoring the limitations of genome-wide association studies as being merely a screening tool.
引用
- Ekenberg C, Tang MH, Zucco AG, et al. Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. J Infect Dis. 2019. PMID: 31219150. doi:10.1093/infdis/jiz294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。